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Abstract
Mitochondria are essential subcellular organelles and important key regulators of 
metabolism. Mammalian mitochondria contain their own DNA (mtDNA). Human 
mtDNA is remarkably small (16,569 bp) compared to nuclear DNA. Mitochondria 
promote aerobic respiration, an important part of energy metabolism in eukaryotes, 
as the site of oxidative phosphorylation (OXPHOS). OXPHOS occurs in the inner 
membrane of the mitochondrion and involves 5 protein complexes that sequentially 
undergo reduction-oxygen reactions ultimately producing adenosine triphosphate 
(ATP). Tissues with high metabolic demand such as lungs, central nervous system, 
peripheral nerves, heart, adrenal glands, renal tubules and the retina are affected 
preferentially by this critical role in energy production by mitochondrial disorders. 
Eye-affected mitochondrial disorders are always primary, but the role of mitochon-
drial dysfunction is now best understood in acquired chronic progressive ocular 
diseases. Recent advances in mitochondrial research have improved our understand-
ing of ocular disorders. In this chapter, we will discuss the mitochondria in relation 
to eye diseases, ocular tumors, pathogenesis, and treatment modalities that will help 
to improve the outcomes of these conditions.
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1. Mitochondria
Mitochondria are essential sub cellular mammalian organelles found in eukary-
otes. It is surrounded by two lipid bilayers which is commonly associated with 
oxidative phosphorylation, a process that meets the majority of cellular energy 
demands. It is involved in many other cellular functions such as fatty acids oxida-
tion, apoptosis, heme biosynthesis, metabolism of amino acids and lipids, and 
signal transduction [1]. They are central organelles controlling the life and death 
of the cell. Mitochondria contain their own DNA, which is maternally inherited. 
Mitochondrial density varies from one tissue to another [2]. Mitochondrial dis-
eases are heterogeneous group of disorders, often characterized by morphological 
changes in the mitochondria, a defective respiratory chain and variable symptoms, 
ranging from severe metabolic disorders with onset in early infancy or childhood 
to late onset adult myopathies [3]. Mutations in mitochondrial DNA (mtDNA) are 
the most frequent cause of mitochondrial diseases in adults. However, the mtDNA 
encodes only a subset of proteins of the different complexes of the respiratory chain 
[4]. Nuclear genes encode all the other mitochondrial proteins and most of the 
mitochondrial disorders are caused by mutations in the nuclear genes [5].
Mitochondria are ~0.5 to ~3 μm long tubular organelles that undergo continu-
ous remodeling of their network by fusion and fission events [6]. Mitochondria 
forms an extensive network preserved in many cells by an intricate balance between 
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fission and fusion, mitochondrial biogenesis and mitophagy [7, 8]. Mitochondria 
was identified as the main source of cell energy, and indeed mitochondria is a 
major site of ATP and macromolecule development. Equivalent-reducing electrons 
are fuelled by the ETC to produce an electrochemical gradient required for both 
the production of ATP and the active transport of selective metabolites, such as 
pyruvate and ATP, through the IMM [9]. Mitochondria, however, plays a variety of 
roles beyond energy production, including generation of reactive oxygen species 
(ROS), redox molecules and metabolites, control of cell signaling and cell death, 
and biosynthetic metabolism.
While mitochondria is best known for harvesting and storage of energy released 
by oxidation of organic substrates under aerobic conditions by respiration, their 
many anabolic functions are often ignored [7]. Biosynthetic functions of mitochon-
dria are essential for tumorigenesis and tumor progression [10]. Tumor cells easily 
survive under hypoxic conditions by recycling NADH to NAD+ through lactate 
dehydrogenase (LDH) and plasma membrane electron transport (PMET) to enable 
continued production of glycolytic ATP [11].
2. Mitochondrial genetics
The human mitochondrial genome consists of 16,569 pairs of nucleotides of 
double-stranded, closed-circular molecules. It was first sequenced in 1981 and 
updated in 1999 [12, 13]. mtDNA contains no introns and only encodes 13 poly-
peptides, 22 transfer RNAs (tRNAs), and the mitochondrial protein synthesis 
genes 12S and 16S rRNA [14]. The 13 polypeptides of the respiratory complexes 
(RC) encode subunits (7 of 45 for RC-I, 1 of 11 for RC-III, 3 of 13 for RC-IV, and 2 
of 16 for RC-V). Along with the remaining 85% of the other RC subunits, the four 
subunits that make up RC-II are nuclear-encoded [14]. About 22,000 proteins are 
encoded by nuclear DNA, about 1,500 of which contribute to the mitochondrial 
proteome. These nuclear encoded proteins include TCA cycle enzymes, amino 
acids, nucleic acid and lipid biosynthesis, mtDNA and RNA polymerases, tran-
scription factors, and ribosomal proteins, in addition to all DNA pathway repair 
components. In the cytoplasm, these proteins are expressed and folded through 
the TOM/TIM complex upon entry through the mitochondrial outer membrane. 
From there, they find the outer mitochondrial membrane (OMM), the IMM, the 
intermembrane space (IMS) or the mitochondrial matrix at their specific positions 
[15]. There is no structural association of mtDNA with histones, as is nuclear DNA. 
Rather, it is closely associated with a variety of proteins, about 100 nm in diameter, 
in discrete nucleoids.
Germline mutations resulting in reduced or lost expression of succinate dehy-
drogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase have 
been identified in inherited paragangliomas, gastrointestinal stromal tumors, 
pheochromocytomas, myomas, SDH, papillary renal cell cancer (FH) and gliomas 
[16]. mtDNA mutations have been involved in neuromuscular and neurodegenera-
tive mitochondrial disease [17–19] and complex diseases such as diabetes [20], 
cardiovascular disease [21, 22], gastrointestinal disorders [23], skin disorders [24], 
aging [25, 26] and cancer. Different human populations have different human 
mtDNA haplotypes, each with a specific mtDNA polymorphism fingerprint, 
transmitted through the maternal germline. These haplotypes are associated with 
the geographic origin of the population. Some human haplotypes are at greater risk 
of developing a certain form of cancer or neurodegenerative disorder during their 
lifetime than others [27–29]. The 22 mitochondrial tRNA genes have more than 50 




The single nucleotide polymorphism, 3243A > G, which alters leucine mt-
tRNA and thus affects the translation of 13 respiratory subunits, leading to fewer 
mitochondrial subunits and impaired OXPHOS, is the most common mtDNA 
mutation [30, 31]. Individuals can develop maternally inherited diabetes and 
deafness with 10–30 percent defective copies of tRNALeu. Mitochondrial enceph-
alomyopathy, lactic acidosis, and stroke-like episodes (MELAS) are likely to occur 
in people with 50–90% defective copies [20, 30–35]. The mutation of tRNALeu 
results in variable types of mitochondrial RC deficiency in various patients. By 
far, complex I (RC-I) deficiency is the most common finding in MELAS, although 
some patients have combined RC-I, RC-III and RC-IV deficiencies [30, 36]. Other 
mutations in mt-tRNA that play a role in human disease include: tRNAlys, which 
is associated with myoclonal epilepsy, tRNASer with deafness, and tRNAIle with 
cardiomyopathy [21].
3. Drivers of mtDNA mutations
mtDNA mutations are caused by ROS-mediated oxidative damage [28, 37]. ROS 
generation in the respiratory chain is an inherent part of OXPHOS. ROS plays an 
important role in many signaling processes and their levels are regulated by the 
antioxidant enzyme systems in the mitochondrial matrix and the IMS. However, in 
situations where OXPHOS is compromised due to misshapen respiratory complexes 
resulting in increased leakage of electrons to oxygen, ROS levels can overwhelm the 
antioxidant protection system and damage to nearby mtDNA [38, 39]. DeBalsi and 
colleagues suggest that errors produced by mtDNA replication and repair machines 
may also cause mtDNA mutations [40].
Human cells contain 17 different human DNA polymerases, but in mtDNA rep-
lication and repair, only polymerase gamma (Pol-γ) functions. A catalytic subunit 
and an accessory subunit consist of a nuclear-encoded Pol-γ holo-enzyme [40]. 
Pol-γ replicates high fidelity mtDNA with one misinsertion in every 500,000 new 
base pairs due to nucleotide selectivity and proofreading capacity [41]. More than 
300 Pol-γ mutations have been associated with human illness, some of which occur 
in adulthood and are associated with aging, including different types of progressive 
external ophthalmoplegia (PEO) and Parkinson’s disease (PD) [40]. The role of 
Pol-γ in restricting mtDNA mutations has been demonstrated by homozygous, but 
not heterozygous, mutator mice with re-reading-deficient Pol-g developing multi-
ple age-related disorders and shortening their lifespan. As their antioxidant capaci-
ties were the same and the degree of oxidative damage was comparable to wild-type 
mice, they acquired mtDNA mutations that were not caused by oxidative damage.
Somatic point mutations, great deletions and several linear deleted mtDNA frag-
ments were acquired by the mutator mice. The mtDNA-specific Twinkle helicase, 
which unwinds mtDNA for Pol-γ synthesis, is another n-mitoprotein involved in 
mtDNA replication [42]. Overexpression of Twinkle in transgenic mice resulted in 
increased copy number of mtDNA and OXPHOS and some twinkle mutations are 
associated with mitochondrial myopathy [40]. Oxidative damage and defective rep-
lication are both likely to add to the overall mutational load of the mtDNA cell, and 
the contribution of each mutational driver is likely to change over time. Inevitable 
respiratory electron leakage from complexes I and III results in the formation of 
superoxide, O2
− that can react with lipids, proteins and DNA [43–46]. Superoxide 
can be quickly converted to H2O2 either naturally or through a manganese super-
oxide dismutase (MnSOD) dysmutation reaction, a resident of the mitochondrial 
matrix. In the presence of redox active metal ions, H2O2 can generate a highly 
reactive hydroxyl radical through the Fenton reaction (OH-) [47]. Multiple mtDNA 
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damage sites, including single and double-strand breaks, abasic sites and base 
changes, are responsible for the OH-radical. Another oxidative burden is caused by 
damage to mitochondrial protein centers caused by O2
− to Fe-S and involves sub-
units of complexes I, II and III as well as aconitase [48–50]. A significant target for 
ROS is provided by Labile Fe-S enzymes such as mitochondrial aconitase.
Mitochondria located in cells exposed to visible light generate ROS through 
interactions with mitochondrial photosensitizers, such as cytochrome c oxidase, 
of particular relevance to the eye, to produce ROS and mtDNA damage [50, 51]. 
Transferring energy from photoactivated chromophores to oxygen contributes to the 
formation of singlet oxygen, 1O2, which occurs in an excited state. 
1O2 can produce 
ROS, such as O2
− by interacting with diatomic oxygen and directly reacting with 
dual-bond electrons without the formation of free radical intermediates [52]. It is 
also important to remember that, from non-mitochondrial sources, various tissues 
within the eye may also produce substantial amounts of ROS. For instance, lipo-
fuscin (an age-related pigment that accumulates with age in RPE cells) is a potent 
photoinducible ROS generator, and NADPH oxidase is considered to be a major 
source of superoxide in microvascular endothelial cells. Studies indicate that ROS 
may also contribute to exogenous mitochondrial oxidative damage, exacerbating 
mitochondrial dysfunction [51, 53, 54].
4. Ophthalmologic mitochondrial dysfunction
Mitochondrial disease can manifest in any organ at any age. In general terms, 
tissues and organs (retina, optic nerve, brain, heart, testis, muscle, etc.) that are 
heavily dependent upon oxidative phosphorylation bear the brunt of the pathology. 
It is also puzzling that many mitochondrial disorders affect multiple organ systems, 
whereas others have a highly stereotyped and organ specific phenotype. These 
subtle interactions between nuclear and mitochondrial genes in health and disease 
will have broader relevance for our understanding of many inherited and sporadic 
disorders.
Mitochondrial disorder can be categorized according to several different criteria 
in the manifestations of ophthalmology diseases. They may be defined as isolated or 
nonisolated, occurring in combination with other manifestations of the organ. The 
dominant trait of the phenotype or a nondominant attribute can be ophthalmologic 
manifestations. Mitochondrial disorders with ophthalmic manifestations may be 
caused either by mutations in mtDNA or nuclear DNA. Ophthalmologic symptoms 
may be unique to syndromic mitochondrial disorder (e.g. Leber hereditary optic 
neuropathy) or nonspecific to syndromic mitochondrial disorder (eg, cataract). 
The cornea, iris, lens, ciliary body, retina, choroid, uvea, or optic nerve may be the 
primary manifestations of ophthalmologic mitochondrial disorder. There is grow-
ing evidence supporting an association between mitochondrial dysfunction and a 
number of ophthalmic diseases causing defects in OXPHOS and increased produc-
tion of ROS triggering the activation of cell death pathway.
5. Corneal dystrophy
Some evidence has been given in recent years that the cornea may be involved 
in mitochondrial disorders. However, systematic studies have not been performed 
on this matter. Astigmatism, corneal dystrophy, corneal clouding, or corneal 
endothelial dysfunction are corneal disorders associated with mitochondrial 




mitochondrial membrane of corneal endothelium, induces oxidative stress and 
cell death, resulting in Congenital Hereditary Endothelial Dystrophy (CHED) with 
corneal edema and vision loss [57]. Fuchs endothelial corneal dystrophy (FECD) 
is characterized by progressive and non-regenerative corneal endothelial loss. 
Variations in mtDNA affect the susceptibility of FECD. Mitochondrial variant 
A10398G and Haplogroup I were significantly associated with FECD [58]. There are 
few studies showing the role of mtDNA in the pathogenesis of FECD. Mitophagy 
activation leads to decrease in Mfn2 gene level and loss of mitochondrial mass in 
FECD [59]. In a study of 20 patients, keratoconus was related to increased oxidative 
stress due to mitochondrial respiratory chain complex-I sequence variation [60]. 
Progressive external ophthalmoplegia secondarily led to persistent conjunctivitis 
and keratitis in a patient with Kearns-Sayre Syndrome [61]. Corneal clouding has 
been documented occasionally in Kearns-Sayre syndrome due to structural changes 
in the endothelium or Descemet membrane [62]. Numerous distended mitochon-
dria were present in the corneal epithelium in a child with Leigh syndrome due to 
the m.8993 T > G mutation [63]. There are also non-specific corneal alterations 
in a patient with Neurogastrointestinal mitochondrial encephalomyopathy [64]. 
Pathogenesis of type 2 granular corneal dystrophy (GCD2) is associated with 
alteration of mitochondrial features and functions that causes mutated GCD2 
keratocytes, particularly in older cells [65].
6.  Mitochondrial encephalomyopathy, lactic acidosis, and episodic 
stroke-like syndrome (MELAS)
Early onset of the disease and higher level of mtDNA heteroplasmy are associ-
ated with a worse prognosis in mitochondrial encephalomyopathy, lactic acidosis, 
and episodic stroke-like syndrome (MELAS). Iris involvement in mitochondrial 
disorders has been rarely mentioned in MELAS [66]. The m.3243A > G variant is the 
most common heteroplasmic mtDNA mutation in MELAS and underlies a spectrum 
of diseases. Patchy iris stroma atrophy has been identified in a patient carrying the 
m.3243A > G mutation in the tRNA (Lys) gene [66]. MNRR1 (CHCHD2) is a bi-
organellar regulator of mitochondrial function, found to be depleted in MELAS and 
significantly associated with m.3243A > G mutation (heteroplasmic) in the mtDNA 
at a level of ∼50 to 90% [67]. Ability of the peroxisome proliferator-activated 
receptor γ (PPARγ) activator pioglitazone (PioG), in combination with deoxyribo-
nucleosides (dNs), improves the mitochondrial biogenesis/respiratory functions in 
MELAS cybrid cells containing >90% of the m.3243A > G mutation that found to 
be novel therapies to treat this disease [68]. Induced pluripotent stem cells (iPSCs) 
are appropriate for studying mitochondrial diseases caused by mtDNA mutations 
in MELAS. Increase of autophagy inpatient-specific iPSCs generated from fibro-
blasts are associated with mtDNA mutations and OXPHOS defects in patients with 
MELAS [69]. Studies demonstrated that defective MRM2 gene causes a MELAS-like 
phenotype which suggests the genetic screening of the MRM2 gene in patients 
with a m.3243 A > G negative MELAS-like presentation [70]. Mutations caused by 
mitochondrial complex I deficiencies by alleviating ketone bodies are also associ-
ated with MELAS that leads to recurrent cerebral insults resembling strokes [71].
7. Cataract
Cataracts are the most common lenticular defects of mitochondrial disorders. In 
mitochondrial disorders, cataract is typically of the posterior subcapsular type [66]. 
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Autophagic dysfunction and abnormal oxidative stress are associated with cataract. 
Cataract may be a phenotypic characteristic of MELAS syndrome, but a patient with 
nonsyndromic mitochondrial disorder due to mtDNA deletion has also been docu-
mented as an initial manifestation [66, 72, 73]. Oxidative stress plays an important 
role in cataractogenesis [74, 75]. Mitochondria are found in the epithelium and 
superficial fiber cells of the lens and it is extremely sensitive to ROS. Interestingly, 
mitochondria have been confirmed as the main source of ROS generation in these 
cell types [76]. A number of in vitro studies have shown that human lens cells are 
particularly sensitive to oxidative insults, where antioxidant activity was inversely 
proportional to the severity of cataracts [77]. Proteins, lipids and DNA oxida-
tion have been found in cataract lenses [78–80]. Under high glucose conditions, 
fluctuations in autophagy and oxidative stress are found in mouse lens epithelial 
cells (LECs) that might attenuate high glucose-induced oxidative injury to LECs 
[81]. Cataract proteins lose sulfhydryl groups, contain oxidized residues, produce 
aggregates of high molecular weight and become insoluble [75]. In addition, cataract 
has been shown to be a symptom of a newly identified mitochondrial disorder called 
autosomal recessive myopathy, caused by growth factor mutations, increased liver 
regeneration gene, which affects protein levels of mitochondrial intermembrane 
space region [82].
8. Leigh syndrome
In mitochondrial disorders, involvement of ciliary body has rarely been reported. 
Leigh’s syndrome is the most common pediatric syndrome, characterized by symmet-
rical brain lesions, hypotonia, motor and respiratory deficits, and premature death 
are associated with pathways involved in mitochondrial diseases [83]. A case report 
showed ocular histopathological finding such as thinning of nerve fibers and ganglion 
cell layers in the nasal aspect of the macula, mild atrophy of the temporal aspect of 
the optic nerve head, and numerous distended mitochondria, non-pigmented cilla 
are associated with the m.8993 T > G mutation in the ATPase6 gene of mtDNA in 
patient with Leigh’s syndrome [63]. In addition, ciliary epithelium was also found 
to be impaired by a long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency [84]. 
Dysfunction of mitochondrial complex I are also associated with many brain patholo-
gies including Leigh’s syndrome. Mitochondrial complex I activity facilitates organis-
mal survival by its regeneration potential of NAD+, while optimal motor regulation 
involves mitochondrial complex I bioenergetic function in Leigh’s syndrome [85].
9. Retinitis pigmentosa
Retinitis pigmentosa is a central characteristic of Kearns-Sayre syndrome and 
neuropathic ataxia retinitis pigmentosa syndrome [72]. Typical for Kearns-Sayre 
syndrome is ‘salt and pepper’ retinitis, with areas of increased and decreased 
pigmentation, especially in the equatorial fundus [62]. Pigment retinopathy is only 
an uncommon characteristic of progressive external ophtalmoplegia and can be 
milder than in Kearns-Sayre syndrome [72, 86]. Only certain patients with MELAS 
or MERRF syndrome have mild posterior pole pigment retinopathy [72]. Mild 
pigmentary defects were also observed in 2 of 20 patients with Leber hereditary 
optic neuropathy due to mutation m.11778G > A [72]. Small pigment retinal defects 
have been identified in a 4-year-old female with a COX deficiency [87]. In addition, 
because of the mutation m.8993 T > GG retinitis pigmentosa has been identified in 




In a sample of 44 Korean Leigh syndrome patients, pigmentary retinopathy was 
also observed in 22% of Korean patients [89]. In a study of 14 patients with pon-
tocerebellar hypoplasia, 4 patients presented with retinopathy without disclosing 
information [90]. Occasionally, retinal dystrophy can manifest with photophobia. 
In a report of 46 mitochondrial disease patients, 4 had photophobia. Two patients 
had Leigh syndrome, 1 of which had rod-cone dystrophy on electroretinography, 1 
had Kearns-Sayre syndrome with regular electroretinography, and 1 had MERRF 
syndrome with isoelectric electroretinography [91].
10. Diabetic retinopathy
It has been shown that mitochondrial dysfunction plays a significant role in 
diabetic retinopathy [92, 93]. Hyperglycemia causes retinal mitochondrial damages 
that plays a central role in the development of diabetic retinopathy. Retinal mito-
chondria undergo elevated oxidative stress in diabetes, and complex III is one of 
the key causes of increased O2
− [94]. Superoxide levels are elevated in in the retina 
of diabetic rats and in retinal vascular endothelial cells incubated in high-glucose 
media [95] and the content of hydrogen peroxide is also increased in the retina of 
diabetic rats [96]. In diabetes, membrane lipid peroxidation and oxidative DNA 
damage, the effects of ROS-induced injury, are elevated in the retina [97]. Chronic 
overproduction of ROS in the retina results in aberrant mitochondrial functions in 
diabetes [92]. Overproduction of superoxide by the mitochondrial electron trans-
port chain caused by hyperglycemia is considered to cause major hyperglycemic 
damage pathways by inhibiting the action of GAPDH. However, it is not yet fully 
understood the mechanism by which hyperglycemia induces an increase in mito-
chondrial ROS, with some suggesting a direct effect and others an indirect function 
via high-glucose-induced cytokines [98–101].
Elevated levels of O2
− activate caspase 3 in retinal capillaries contributes to cell 
death [92]. Upregulation of superoxide dismutase (SOD2) inhibited increased 
mitochondrial O2-induced diabetes, restored mitochondrial function, and pre-
vented both in vitro and in vivo vascular pathology [94, 102–104]. However, the 
timing of such therapies is important because animal studies have shown that oxi-
dative stress not only leads to the development of diabetic retinopathy, but also to 
the resistance of retinopathy to reversal [105]. The resistance to reversal of diabetic 
retinopathy may be due to the accumulation of weakened mitochondrial molecules 
and ROS-induced damage that is not readily removed even after the restoration 
of high glycemic control. However, the accumulation of advanced glycation end 
products is also involved in metabolic memory [106]. The mtDNA variation has 
also been associated with resistance to type 1 diabetes. A single nucleotide modi-
fication (C5173A) is associated with resistance to type 1 diabetes in the Japanese 
population, resulting in a leucine-to-methionine amino acid substitution in the 
mitochondrially encoded NADH dehydrogenase subunit 2 gene [107]. Similarly, 
in comparison with the diabetes-prone nonobese diabetic mouse strain, ortholo-
gous polymorphism (C4738A), resulting in L-to-M substitution, offers resistance 
against the development of spontaneous diabetes [108]. Gusdon et al., have shown 
that the replacement of methionine results in a lower level of development of ROS 
from complex III [109].
The product of mtDNA mutations is also known to result in many syndromic 
central nervous system diseases. The most common retinal pathology is pigmentary 
retinopathy, while optic neuropathy is an uncommon finding in these disorders. 
Neurogenic atrophy and retinitis pigmentosa syndrome results from point muta-
tions in the mtDNA ATPase-6 gene, usually T8993G variation. Patients usually 
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present with retinitis pigmentosa with or without optic neuropathy and may 
develop dystonia [110]. Several mtDNA point mutations may result from MELAS, 
although the A3243G mutation in the tRNALeu gene is the most common. Patients 
with MELAS undergo stroke-like episodes leading to recurrent retrochiasmal vision 
loss, but sometimes even to pigmentary retinopathy without optic atrophy [111]. 
Its contribution to the pathogenesis of maternally inherited diabetes and deaf-
ness is also evidenced by the spectrum of disease resulting from the A3243G point 
mutation [112–114]. This is a multisystemic disease characterized by sensorineural 
deafness, retinal defects and diabetes, generally occurring in the third to fourth 
decades of life [115]. The second phenotype is a pattern dystrophy, with diffuse 
granularity and pigment clumping, marked by relative sparing of the fovea, and 
retinal pigment epithelium within the vascular retinal arcades. However, with a 
strong prognosis, visual acuity is retained, despite the degree of atrophy [116, 117].
11. Macular degeneration
Age-related macular degeneration is a neurodegenerative late-onset disorder that 
shares certain characteristics of Alzheimer’s disease. In most cases, the build-up of 
protein plaques, known as drusen, in the central macular area of the retina involves 
age-related macular degeneration. Both age-related macular degeneration and 
Alzheimer’s disease pathogenesis can be driven by stress stimuli, including oxidative 
stress, aging, genetic factors and inflammation, including the deposition of protein 
plaques in the retina or brain [98]. Similarities in these two disorders are also found 
in the risk factor gene polymorphisms, APOE, associated with age-related macular 
degeneration [99, 100] and Alzheimer’s disease [101, 102]. The APOE gene controls 
the homeostasis of triglycerides and cholesterol [103], and the loss of function of 
APOE has been correlated with the deposit of senile plaques, consisting mainly 
of amyloid beta peptide [104], which is produced in drusen [105, 106] and is also 
associated with an additional risk factor for age-related macular degeneration, i.e. 
complement protein [107, 108]. Evidence shows that the APOE genotype can dictate 
the risk of stress stimuli, including oxidative stress, aging, genetic factors and 
inflammation, including the deposition of protein plaques in the retina or brain, can 
drive both age-related macular degeneration and Alzheimer’s disease pathogenesis. 
Alzheimer’s disease and other chronic disorders, primarily because of its effect on 
regulation of oxidative stress [109]. Age-related macular degeneration is split into 
two main forms, i.e. the “wet” form induced by leakage into the subretinal space 
from choroidal neovascularization and the more common “dry” form associated 
with the accumulation of drusen in the macula [75]. In patients with age-related 
macular degeneration, there is an increased incidence of large-scale mtDNA rear-
rangements and deletions in blood [76] and retinas [77, 78]. In the non-coding 
mtDNA control area (d-loop) in retinas with age-related macular degeneration, 
which has been found in Alzheimer’s disease and other conditions of oxidative 
stress, there are also increased rates of single nucleotide polymorphisms [79]. An 
increased rate of mtDNA deletions and single nucleotide polymorphisms are likely 
to decrease the amount and density of mitochondria [80].
Other than pigmentary retinopathy or macular degeneration, retinal anomalies 
include retinal dystrophy, retinal hypertrophy, and pigmentary maculopathy. 
Patients with Kearns-Sayre syndrome, Leigh syndrome, MELAS syndrome, 
MERRF syndrome, and Leber hereditary optic neuropathy will find retinal 
dystrophies that are most easily measured by electroretinography [91]. Retinal 
hypertrophy has been identified in patients with autosomal recessive spastic 




Charlevoix-Saguenay (ARSAL/ARSACS) [118]. Six affected males in a family with 
Mohr-Tranebjaerg syndrome had blindness resulting from unexplained retinal 
degeneration [119]. Treatment options for retinopathy are usually limited.
12. Choroidal dystrophy
Choroid and uvea are occasionally affected by mitochondrial disorders. Choroid 
atrophy is the most common manifestation of mitochondrial disorders [66]. 
Choroidal atrophy was especially identified in the sense of MELAS syndrome [66]. 
Choroid pigment epithelium atrophy also occurs in maternally inherited deafness 
and diabetes [120]. Central choroidal dystrophy was identified in 1 patient with 
Mohr-Tranebjaerg syndrome as confirmed by electroretinography [119]. In addi-
tion, chorioretinal dystrophy was reported in a single patient with a significant 
deletion of mtDNA [121].
13. Uveitis
A significant causative factor causing blindness from retinal photoreceptor 
degeneration is intraocular inflammation, also referred to as uveitis. Activated 
macrophages, which generate various cytotoxic agents, including inducible 
nitric oxide generated by inducible nitric oxide synthase, O2
− and other ROS, are 
responsible for oxidative retinal damage in uveitis [122]. Oxidative stress plays an 
important role in the early stages of experimental autoimmune uveitis (EAU) in 
the photoreceptor mitochondria. mtDNA damage has been shown to occur early in 
the EAU; interestingly, nDNA damage occurred later in the EAU [123]. In addition, 
peroxynitrite-mediated nitration modifies mitochondrial proteins in the inner seg-
ments of the photoreceptor, which, in turn, contributes to increased mitochondrial 
ROS generation [124]. MnSOD has been shown to be upregulated during EAU to 
promote an increased state of mitochondrial oxidative stress, possibly to combat 
ROS [125]. In the early phase of the EAU, before leukocyte infiltration, recent data 
seem to indicate a causative function of oxidative mtDNA harm. Such mitochon-
drial oxidative damage can be the initial event that contributes to retinal degenera-
tion in uveitis [123].
14. Optic atrophy
Optic atrophy is the principal mitochondrial dysfunction manifestation of the 
optic nerve. Optic atrophy is a prevalent manifestation of mitochondrial disorder 
but is often overlooked or misinterpreted. This is due to the difficulties of optic 
atrophy diagnosis. Funduscopy can more reliably determine optic atrophy if the 
distal portion of the optic nerve is impaired, or if the more proximal portions of 
the nerve are affected by orbital magnetic resonance imaging (MRI). A decreased 
amplitude of visually evoked potential is a sign of optic nerve atrophy [126]. Optic 
atrophy has been specifically identified in Leber hereditary optic neuropathy and 
autosomal dominant optic atrophy among syndromic mitochondrial disorders, 
conditions in which optic atrophy is the dominant phenotypic function [127]. 
MELAS syndrome, Kearns-Sayre syndrome, Pearson syndrome, pontocerebellar 
hypoplasia, Mohr-Tranebjaerg syndrome, Alpers-Huttenlocher disease or Wolfram 
syndrome have been documented more rarely, with optic atrophy [62, 90, 91, 127]. 
In patients with MERRF syndrome, partial or complete optic atrophy has also been 
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identified [72, 91, 128]. Optical atrophy is a common phenotypic characteristic of 
inherited motor and sensory neuropathy type VI (HMSN-IV) due to MFN1 muta-
tions [127]. In addition, C12orf65 (COXPD7) mutations manifest phenotypicly 
with optical atrophy and Leigh-like phenotype [129]. Optical atrophy associated 
with neuropathy ataxia retinitis pigmentosa syndrome due to m.8993 T > G muta-
tion in the ATPase6 gene was only seen in a single family [110]. In a study of 44 
Korean patients with Leigh Syndrome, 22.5 per cent of optical atrophy was identi-
fied [89]. Optical disk alterations have been observed only in a single patient with 
mitochondrial neurogastrointestinal encephalomyopathy [64]. Optical atrophy can 
also be a characteristic of childhood-onset spinocerebellar ataxia [130] or mito-
chondrial depletion syndrome. 39 Non-syndromic mitochondrial optic atrophy 
disorders is attributed to ACI1 mutation [131], due to ND5 mutation with cataract 
and retinopathy [132].
15. Glaucoma
Increased intraocular pressure (Glaucoma) is an unusual phenotypic character-
istic of mitochondrial disorders. There are two primary types of glaucoma that can 
be distinguished, open-angle glaucoma and closed-angle glaucoma. In addition, 
normotensive and hypertensive glaucoma are distinguished. Open-angle glaucoma 
is seldom observed in patients with Leber inherited optic neuropathy or autosomal 
dominant optic atrophy. Funduscopic findings can indicate a mixture of abnormali-
ties common for glaucoma retinopathy and an inherited Leber optic neuropathy 
fundus [133]. In a single patient with mitochondrial neurogastrointestinal encepha-
lomyopathy, glaucomatous changes in the optic disc were observed by visual field 
assessment and optical coherence tomography [64]. In a study of 14 patients with 
pontocerebellar hypoplasia, one presented with glaucoma [90]. Normal pressure 
glaucoma is associated with polymorphism in the OPA1 gene [134].
Glaucoma has also been identified in a family with Wolfram Syndrome. There 
are signs that ND5 mutations are associated with the development of open-angle 
glaucoma. Glaucoma in mitochondrial disorders may be eligible for treatment 
with drugs or surgery [135, 136]. There is evidence in glaucoma that mitochondrial 
dysfunction can reduce the bioenergetic status of retinal ganglion cells, leading to 
increased susceptibility to oxidative stress and apoptotic cell death [93, 137]. Light 
exposure may also be an oxidative risk factor, reducing mitochondrial function and 
increasing the development of ROS in ganglion cells [138]. A defective mitochon-
dria has been highly implicated in neuronal apoptosis in the experimental models 
of glaucoma [139, 140]. The mtDNA abnormalities further support the importance 
of mitochondrial dysfunction-associated stress as a risk factor for glaucoma 
patients [141].
16. Nystagmus
The central nervous system or vestibular involvement in mitochondrial 
disorders may cause nystagmus or roving eye movements and are the most com-
mon ophthalmological manifestations as a symptom in patients with pediatric 
mitochondrial disorder [142]. A Gaze-evoked nystagmus identified in a single 
patient with “Leber hereditary optic neuropathy plus” who not only possessed the 
“m.11778G > A” mutation in the hereditary Leber hereditary optic neuropathy gene 
but also the “m.3394 T > C” mutation [143]. Since patients with MELAS may display 




eye movement may show abnormally slow saccadic reactions, prolonged saccades, 
impaired suppression of reflex eye movements, prolonged reaction during antisac-
cades, square-wave jerks, or impaired chase [144]. Patients have epilepsy due to 
MELAS may have epileptic nystagmus, disrupted smooth pursuit, or transient eye 
divergence, none of which are outward signs [145]. In addition, nystagmus was 
documented in a patient carrying a point mutation in the DGUOK gene who also 
had retinal blindness. Nystagmus, which is a common symptom of the disease 
along with retinitis pigmentosa, was also reported in a patient with nonsyndromic 
mitochondrial disorder due to the m.15995G > A mutation in the tRNA (Pro) gene 
manifesting as ataxia, deafness, and leukoencephalopathy [146]. Nystagmus was 
part of the phenotype in a study of 7 Czech patients with autosomal dominant optic 
atrophy [147]. Nystagmus is also a common characteristic of ARSAL/ARSACS [148]. 
Nystagmus was observed in 14 percent in a study of 44 Korean patients with Leigh 
syndrome [88].
17. Strabismus
Strabismus was the most common ophthalmologic abnormality in a study of 44 
Korean patients with Leigh syndrome and was present in 41% of patients [89]. Of 
the strabismus patients, 13 had exotropia and 5 had esotropia [89]. In some patients 
with X-linked sideroblast anemia with ataxia, strabismus has also been identified 
[149]. In 25 percent of juvenile mitochondrial disorders, divergent strabismus has 
been identified as the presenting manifestation [150]. In a study of 14 patients with 
pontocerebellar hypoplasia, of whom 13 had a CASK mutation, 2 had strabismus. 9 
Strabismus was also identified without knowing the underlying mutation in other 
patients with pontocerebellar hypoplasia [151, 152]. The initial presentation at birth 
was cataract and strabismus in a child with a significant mtDNA deletion. Later 
on, he experienced Leigh-like pathologies and episodes of stroke [153]. In certain 
instances, surgery can have a beneficial effect on strabism.
18. Progressive external ophthalmoplegia
In mitochondrial disorders, affectation of the extraocular muscles results in 
progressive external ophthalmoplegia. The recurrent ophthalmologic manifestation 
of mitochondrial disorders is progressive external ophthalmoplegia. It may be com-
plete, resulting in, or partial, walled-in bulbs. Both directions of bulb movements or 
only some of them can be affected. One eye or both eyes can be affected by it. Single 
or multiple mtDNA deletions are most often associated with progressive external 
ophthalmoplegia. Progressive external ophthalmoplegia, Kearns-Sayre syndrome 
or Pearson syndrome can cause single mtDNA deletions [154]. Multiple deletions of 
mtDNA may be due to mutations in nuclear genes such as PEO1, POLG1, SLC25A4, 
RRM2B, POLG2, or OPA1, along with progressive external ophthalmoplegia [154]. 
In addition, progressive external ophthalmoplegia, especially in the transfer of 
RNA (eg, tRNA(Lys)) genes, may be due to mtDNA point mutations [154]. Transfer 
RNA mutations with progressive external ophthalmoplegia are mostly sporadically 
similar to mtDNA deletions and can only be observed in muscle deletions [155]. The 
sole manifestation of the m.3243A > G mutation, which often manifests as MELAS 
syndrome, may be progressive external ophthalmoplegia [156]. In a patient with 
mitochondrial neurogastrointestinal encephalomyopathy, progressive external 
ophthalmoplegia was a phenotypic feature [64], Wolfram syndrome [157], Leigh 
syndrome, autosomal dominant optic atrophy, and mitochondrial recessive ataxia 
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syndrome. In MERRF syndrome, progressive external ophthalmoplegia has also 
been described [158].
Infantile-onset spinocerebellar ataxia is a Finnish disorder, with some of the 
24 cases identified to date developing ophthalmoplegia [130]. Ophthalmoparesis 
is a hallmark of sensory ataxic neuropathy with ophthalmoparesis syndrome and 
dysarthria [159]. Sensory ataxic neuropathy with dysarthria and ophthalmoparesis 
is due to mutations in either the POLG1 or PEO1 gene resulting in multiple mtDNA 
deletions [159]. Furthermore, ophthalmoparesis can be observed in patients with 
mitochondrial depletion syndrome [160] or nonsyndromal mitochondrial disorders 
[161]. In patients with Leber inherited optic neuropathy and progressive external 
ophthalmoplegia, ultrastructural variations in muscle biopsy from the extraocular 
muscles clearly differ [162].
19. Eyelid
Ptosis is one of the most common forms of mitochondrial dysfunction. It 
can occur unilaterally at onset, but during the course of the disease, it usually 
becomes bilateral. Ptosis can be the sole manifestation, particularly at the onset of 
the disease, of a mitochondrial disorder or associated with other manifestations. 
Particularly at the onset of the disease, ptosis can show dynamic alterations, leading 
to misinterpretation as myasthenia gravis [163]. Ptosis may be discrete, especially 
at initiation, so that it is missed on clinical review. Progressive external ophthal-
moplegia or other ocular symptoms of mitochondrial disease can be associated 
with ptosis. Ptosis of syndromic as well as nonsyndromic mitochondrial disorders 
may be a phenotypic manifestation. In particular, ptosis was identified in progres-
sive external ophthalmoplegia, MELAS, MERRF, Kearns-Sayre syndrome, sensory 
ataxic neuropathy with dysarthria and ophthalmoparesis [164], Pearson syndrome, 
mitochondrial neurogastrointestinal encephalomyopathy, and autosomal domi-
nant optic atrophy, among the syndromic mitochondrial disorders [91]. Ptosis 
was present in 16 percent in a group of 44 Korean patients with Leigh syndrome 
[89]. Ptosis was also present in isolated cases of maternally inherited deafness and 
diabetes [156], mitochondrial neurogastrointestinal encephalomyopathy [64], or 
mitochondrial depletion syndrome [160]. Poor lid closure was found in a Persian 
Jew with mitochondrial myopathy, lactic acidosis, and sideroblastic anemia due to a 
PUS1 mutation [165].
20. Leber hereditary optic neuropathy
Leber hereditary optic neuropathy is a maternally inherited blindness condi-
tion caused by gene mutations encoding the respiratory-chain complex I sub-
units. Nearly 90 percent of all cases of Leber inherited optic neuropathy contain 
mutations in 3 genes [128]. The m.3460A > G mutation in the ND1 gene, the 
m.11778G > A mutation in the ND4 gene and the m.14484 T > C mutation in the 
ND6 gene are the 3 most common Leber hereditary optic neuropathy mutations 
(primary Leber hereditary optic neuropathy mutations) [128]. Leber inherited 
optic neuropathy is clinically characterized as bilateral, painless, subacute vision 
impairment that occurs during young adult life [134].
Compared with women, Leber hereditary optic neuropathy is 4 to 5 times more 
common in males. Individuals affected are usually completely asymptomatic until 
they experience visual blurring in 1 eye affecting the central visual field [134]. On 




visual acuity is greatly diminished or even worse when counting fingers, and visual 
field examination reveals an expanded central or ceco-central thick scotoma [134]. 
After the acute process, the optical disks become atrophic. Funduscopic find-
ings characteristic of Leber inherited optic neuropathy include microangiopathy, 
hyperemic disks, retinal telangiectasis (ectatic capillaries), peripapillary microan-
giopathy, and tortuosity of vessels (twisted vessels). (twisted vessels). The orbital 
MRI can display atrophy of the nerve with a compensated widening of the space 
below the optic sheath. Mutations in mitochondrial ND3, ND4, or ND6 genes can 
cause hereditary Leber optic neuropathy with dystonia [166].
21. Autosomal dominant optic atrophy
Autosomal dominant optic atrophy is a blindness condition which does not dis-
play a gender disparity, unlike Leber inherited optic neuropathy [127]. It is caused 
by mutations in the nuclearly encoded OPA1 gene [127]. Autosomal dominant optic 
atrophy can also be due to OPA3 mutations that are associated with cataract [167]. 
Progressive, painless, bilateral symmetrical vision loss clinically characterizes 
autosomal dominant optic atrophy [154]. Central, ceco-central, or para-central 
scotomas, consistent with early involvement of the papillo-macular bundle, are the 
most common visual field anomalies in autosomal dominant optic atrophy [154]. 
OPA1 mutations can manifest not only with optic atrophy in some families, but also 
with progressive external ophthalmoplegia, ptosis, and hypoacusis [168]. Since 
glaucoma neuropathy, autosomal dominant optic atrophy, and Leber hereditary 
optic neuropathy often have similar changes in the topographic optic disc, they 
cannot be discriminated against alone by disc evaluation [169]. There is currently 
no appropriate treatment available.
22. Retinoblastoma
Retinoblastoma (Rb) is the most common intraocular cancer in children that 
arise from retinal precursor cells. Electron microscopy revealed numerous mor-
phological and pathological changes in mitochondria of retinoblastoma patients. 
Cristolysis and degenerated mitochondria were the most frequently observed 
features in Rb [170]. A study suggested that T16519C, C16223T, A263G and A73G 
mtDNA D-Loop mutations plays a significant role in the etiology of retinoblas-
toma. This was the first study to examine the mtDNA D-loop mutation in retino-
blastoma and its correlation with various parameters and patient outcome [171]. 
Their findings imply a strong inhibition of mitochondrial oxidative phosphoryla-
tion complexes in these patients. Loss of mitochondrial complex I was found in 
majority of the cases whereas expression of mitochondrial complex III, IV and V 
were found in more than 50% of the cases. Expression of mitochondrial complex 
I was associated with good prognosis and better overall survival [172]. Another 
consequence of alteration in OXPHOS complexes is an increased production of 
reactive oxygen species (ROS). NADPH oxidases (NOX4) are a major intracel-
lular source of ROS and it was found to be overexpressed in retinoblastoma [173]. 
Increased expression of ROS and decreased expression of OXPHOS complexes 
modulates the apoptotic pathway involved in mitochondria by altering BCl-2 
family proteins. Singh et al. showed a differential expression of apoptotic regula-
tory proteins (Bax, BCl-2, PUMA and p53) where they found increased expression 
of BCl-2 and PUMA along with loss of Bax and p53, which might contribute to 
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23. Conclusion
Researchers found that these findings are important because they indicate that 
mtDNA damage can be caused by both spontaneous ROS and by inherited mtDNA 
mutations. Continued study in this clinically important area would certainly 
provide a better understanding of how deficiencies/mutations of the mitochondrial 
genome contribute to the pathogenesis of ocular diseases. The biggest problems 
with the future of mitochondria are the advancement of therapeutic strategies to 
target mitochondria and modify its DNA using nucleotide precursors to retain mito-
chondrial integrity. These therapeutic strategies can potentially be used to block or 
slow down the effects of mitochondrial disease in future.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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